An Elsevier journal has retracted a paper coauthored by a deputy department chair at Thomas Jefferson University in Philadelphia and says it plans to retract at least two more of his articles for image-related concerns. The 2022 paper, in Matrix Biology, describes the regulatory role of proteoglycans in remodeling of the cervix during pregnancy. According … Continue reading Deputy department chair loses paper for image duplication, more retractions to follow| Retraction Watch
Editor’s note: Mahmood Anwar is a former business management professor of the National Research University in Tashkent, Uzbekistan. In the course of his research, he keeps an eye out for flawed articles, he told Retraction Watch. He currently mentors 10 to 15 researchers who found him through his YouTube channel, where he discusses research ethics … Continue reading Guest post: In the name of Scopus, one hijacked journal easily tricks authors| Retraction Watch
Schneider Shorts 29.08.2025 - Little Britain special with an old crab in China, Glasgow maffia, a greedy dame, perks under the holly, and a citations improvement regime, plus peculiar corrections, and the health benefits of red meat and red light.| For Better Science
This Coffee Time includes OX.DH achieving compliance with the NHSE Tech Innovation Framework and a report on clinicians' attitude towards AI.| Digital Health
Seven papers on various aspects of vaping and cigarettes published in Toxicology Reports listed each authors’ affiliation – the tobacco company Philip Morris International – when they origina…| Retraction Watch
“Since Journal of Ethnopharmacology sees no reason to reject bear bile powder research like other scientific journals, that means you can expect to see anything there” – Parashore…| For Better Science
Yesterday, Retraction Watch published a piece about a notorious 2020 article by Gautret et al that had promoted the idea that hydroxychloroquine could treat COVID-19. Despite numerous concerns, the article has not been retracted from the International Journal for Antimicrobial Agents, a journal that is co-owned by the publisher, Elsevier, and The International Society of Antimicrobial Chemotherapy (ISAC). | BishopBlog
There is widespread (even if not universal) agreement that something is deeply wrong with the current system of academic publishing. The basic point, which has been made innumerable times by innumerable people, is that the really hard parts — the writing of papers, and the peer review and selection of the ones to publish — […]| Gowers's Weblog
This post is principally addressed to academics in the UK, though some of it may apply to people in other countries too. The current deal that the universities have with Elsevier expires at the end…| Gowers's Weblog
Schneider Shorts 15.11.2024 – trouble in elite Canadian lab, leadership chaos at IEEE, cancer charity money put to good use in Italy, one Elsevier journal untouchable, another cleaned from pa…| For Better Science
“I woke up seeing Elsevier’s giant middle finger in front of my face.” – Mu Yang| For Better Science
Today's links| Pluralistic: Daily links from Cory Doctorow
To learn about how Scopus AI works under the hood, we interview Elsevier Sr. VP of Analytics Products and Data Platform, Maxim Khan| The Scholarly Kitchen
Since 2012, thousands of academics have been boycotting the academic publisher Elsevier, whom they blame for overpricing its journals, and more generally for resisting open access to the scientific literature. Of course, most major academic publishers are guilty of the same, but Elsevier stands out as the worst offender. For instance, Elsevier was the last major publisher to join the Initiative for Open citations, years after all the others. Elsevier did not join the Initiative for open abstr...| Research Practices and Tools
After a coalition of European science funding agencies announced their Plan S initiative for open access, a number of researchers wrote an open letter criticizing the move, under the title “Reaction of Researchers to Plan S: Too Far, Too Risky”. To summarize, they fear that Plan S would increase costs, lower quality, and restrict academic freedom. In order to evaluate how seriously these fears should be taken, let me start with a 5-point analysis of the issues, before discussing the open ...| Research Practices and Tools
After long and tortuous negotiations, the French consortium Couperin has claimed victory in its recent agreement with Springer, after having secured price decreases. This claim seems reasonable, as prices of big deals with publishers tend to increase steadily. Of course, critics can still point out that Springer remains very expensive compared to smaller, more efficient publishers. But at least Springer seems amenable to some compromises in negotiations. And one should not forget that the gre...| Research Practices and Tools
If you are a postdoctoral researcher between jobs, you can apply for free access to all Elsevier/ScienceDirect scholarly articles here. It seems like all you need is a letter on official letterhead…| Motivic stuff